Close

Chlamydia

Chlamydia is the most common sexually transmitted disease and it is caused by the bacterium Chlamydia trachomatis. It affects 5% to 10% of the world’s population and it is particularly common in young adults under 25 years. It is a major public health concern due to its prevalence and potential long-term consequences.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Filter By:
Clear Results
19 Results
Name
Type
Format
Host/Source
Isotype
Tested Apps
Unit
Catalog
SDS
COA
Request Sample
MAb to Chlamydia Trachomatis
Monoclonal
Purified
Mouse
IgG2a,k
N/A
MG
MAV06-086
MAb to Chlamydia Species LPS
Monoclonal
Purified
Mouse
IgG2b,k
EIA
MG
MAV07-743
MAb to Chlamydia Species LPS
Monoclonal
Purified
Mouse
IgG2b,k
EIA
MG
MAV07-347
C. Trachomatis LGV Type-2 EB
Antigen
Purified
Mouse L Cells
N/A
EIA
ML
R02121
MAb to Chlamydia Trachomatis
Monoclonal
Purified
Mouse
IgG3,k
IFA, IHC(p)
MG
C66435M
Goat anti C. Trachomatis EB
Polyclonal
FITC
Goat
N/A
IFA
ML
B65252G
Goat anti C. Trachomatis EB
Polyclonal
Purified
Goat
N/A
EIA, IFA
ML
B65256G
Rabbit anti C. Trachomatis EB
Polyclonal
Purified
Rabbit
N/A
EIA, IFA
ML
B65256R
Goat anti C. trachomatis MOMP
Polyclonal
Purified
Goat
N/A
IFA
ML
B65266G
Rabbit anti C. Trachomatis EB
Polyclonal
FITC
Rabbit
N/A
IFA
ML
B65252R
Rabbit anti C. Trachomatis EB
Polyclonal
HRP
Rabbit
N/A
EIA, ICC
ML
B65253R
Goat anti C. trachomatis MOMP
Polyclonal
Biotin
Goat
N/A
IFA
ML
B65261G
MAb to Chlamydia Species
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, IHC(p)
MG
C65168M
MAb to Chlamydia Species
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, IHC(p)
MG
C65815M
MAb to Chlamydia
Monoclonal
Purified
Mouse
IgG3,l
IFA, IHC(p)
MG
C66436M
MAb to Chlamydia Species
Monoclonal
Purified
Mouse
IgG2b
EIA
MG
C01365M
MAb to C. trachomatis LPS
Monoclonal
Purified
Mouse
IgG
LF, Pr
MG
C01566M
MAb to C. trachomatis LPS
Monoclonal
Purified
Mouse
IgG
LF, Pr
MG
C01565M
MAb to Chlamydia Trachomatis
Monoclonal
Purified
Mouse
IgG2a
EIA, IFA, IHC
MG
C01363M

Chlamydia trachomatis

An estimated 100 million Chlamydia trachomatis infections occur annually among sexually active adolescents and young adults in the world. Its prevalence is due to most infections (75% of women and 50% of men) going undiagnosed and spreading the disease unknowingly. Most infections cause minimal to no symptoms, and if left untreated, can lead to non-gonococcal urethritis in men and several inflammatory reproductive tract syndromes in women such as inflammation of the uterine cervix and pelvic inflammatory disease (PID). Over time in women 20% will become infertile, 18% will experience debilitating, chronic pelvic pain, and 9% will have a life-threatening tubal pregnancy. Furthermore, C. trachomatis infection during pregnancy leads to infant conjunctivitis and pneumonia and maternal postpartum endometriosis.

In most cases, chlamydia can be easily treated with antibiotics with a cure rate of 95%. It is recommended that young adults under age 25 and others at high risk (e.g. pregnant women) should be tested for chlamydia once a year even if they are symptom-free.

Diagnosis

Culture testing for C. trachomatis has been the reference standard, however antigen detection using ELISA-based assays, direct fluorescent antibody (DFA) tests and nucleic acid hybridization tests have increased in popularity due to their relative ease-of-use. EIA methods initially developed for the detection of C. trachomatis measured lipopolysaccharide (LPS) antigen expressed by the chlamydial elementary bodies which is common to all four chlamydia species (C. trachomatis, C. pneumoniae, C. psittaci, and C. pecorum). Newer tests for C. trachomatis use antibodies against chlamydial heat shock protein 60 (cHSP60) or the major outer membrane protein (MOMP) which do not cross-react with the other chlamydia species or with other organisms that contain LPS.

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue

Continue
EN